A rejection from an ACS journal is a common experience in chemistry, and the search that follows is almost as common. Within hours of a decision letter, many authors type ACS Publications alternatives or journals like ACS into a search box, often before they have read the letter closely. That order is understandable, but it is backwards. The next journal should follow from why the last one said no, not from the first name that comes to mind.
This guide walks through how to narrow the field after an ACS decision. It covers how to read the reason for rejection, which publishers sit closest to ACS in chemistry and related fields, what to check on open access and charges, and how to avoid resubmitting a paper whose disclosure statements and reporting checklists no longer fit the new target. Journal policies change, so treat every specific claim here as a prompt to check the current author guidelines, not as a substitute for them.
Working Principle
Choose the next journal from the reviewers' reasons, not from your preference. A paper that was turned down for scope needs a different home. A paper that was turned down for missing experiments needs those experiments, and no journal change will fix that.
Why Authors Look Beyond ACS Publications
ACS is one of the largest publishers in chemistry. Its portfolio runs from the Journal of the American Chemical Society through a long list of specialist titles in catalysis, materials, analytical chemistry and medicinal chemistry, and it includes ACS Central Science, the society's open access flagship. That breadth is an advantage for authors, because a paper can usually find a plausible ACS home. It also explains why a rejection from one ACS title is often followed by a submission to a sister title out of habit, even when the reviewers were pointing somewhere else entirely.
Authors leave the ACS family for three reasons that come up again and again in editorial advice. The first is scope. The science is sound, but it belongs to a neighboring readership, such as a materials study written for biologists or a catalysis paper that reads more naturally as applied engineering. The second is cost and access. An author whose institution has no relevant ACS agreement may find an article processing charge hard to justify, or may need a route that satisfies a funder's public access rule. The third is editorial fit. The journal's stated priorities have moved away from the paper, even though the topic has not.
The ACS catalog itself also changes. In January 2026, ACS announced that Environmental Health Perspectives had joined its portfolio, and said that article publishing charges would be waived for manuscripts submitted through the end of 2026 while the journal remained fully open access. For health-related chemistry, toxicology and exposure science, that is a reminder to check the current ACS portfolio rather than assume the list you remember is still the list.
Diagnose the Rejection Before You Choose a Journal
Read the decision letter three times: once for the reasons, once for the tone, and once for anything the editor left unsaid. Most decision letters fall into a few categories, and each one points to a different next step.
A scope rejection says the paper is outside the journal's remit. The fix is to move sideways, to a journal whose stated scope names your question, rather than down to a lower-profile version of the same journal. Look at the last year of articles in each candidate and ask whether your paper would sit comfortably among them. If the answer is no for the question and the method, the scope problem is real.
A significance rejection says the advance is real but not large enough for this readership. Papers in this category often do well at a respected specialist title, and the sensible target is usually the next tier at the same level of prestige, not a title several rungs below. Authors who skip this distinction tend to spend months on journals that were never going to take the paper at its current level of claim.
A methodological rejection says reviewers found a gap. Missing controls, underpowered comparisons, unsupported mechanistic claims and incomplete characterization do not disappear when you change journals. Address them first. No other editor will overlook a gap that two reviewers have already named.
Some letters say very little. In that case, email the editorial office with one specific question, such as whether the concerns were about fit or about the experimental evidence. A short factual question is far more likely to get a useful reply than a request for general advice on where to go next.
Chemistry Alternatives Outside ACS, Grouped by Publisher
Chemistry has a stable set of publishers whose titles compete directly with ACS journals. Start by checking which neighbor covers your subfield, then compare the two or three titles that look closest.
The Royal Society of Chemistry publishes the closest cousins of many ACS titles. Chemical Science is a broad, fully open access chemistry journal from the RSC, and Chemical Communications suits shorter reports where speed matters. Green Chemistry and the RSC's materials, analytical and biomolecular titles serve more specialized readerships. RSC processes describe an option to transfer some rejected papers to another RSC journal, with the receiving editor deciding whether further review is needed. Ask about that possibility when the decline arrives, because the answer changes your timeline.
Wiley-VCH publishes Angewandte Chemie and Chemistry, A European Journal, both of which compete with high-profile ACS titles for broad synthetic and mechanistic work. Angewandte is the usual comparator for JACS-level chemistry, though its editorial standards and reviewer pool differ, so a rejection there is not a verdict on the paper's value. Advanced Science, also from Wiley, is an interdisciplinary open access option for papers that bridge chemistry with materials science, biology or engineering.
At the high end of the market, Cell Press publishes Chem for work with a strong mechanistic or conceptual story, and Springer Nature publishes Nature Chemistry. Nature Chemistry is highly selective, and a rejection there is often about perceived significance rather than correctness, so a strong second choice is frequently a top chemistry title with a clear fit rather than a lower-profile journal. Springer Nature also publishes Communications Chemistry, an open access option that can suit sound work with a wide audience.
Medicinal Chemistry: Where Papers Usually Go Next
The most common ACS exit for medical authors is the Journal of Medicinal Chemistry, and the search for alternatives changes when the paper is about a compound rather than a reaction. Pharmaceutical chemists who are declined there often look first at European Journal of Medicinal Chemistry from Elsevier, which covers similar ground in drug design and structure-activity work. RSC Medicinal Chemistry suits shorter or more interdisciplinary studies, and ChemMedChem from Wiley-VCH serves medicinal chemistry with a chemical biology emphasis.
Work at the boundary between chemistry and biology may fit ACS Chemical Biology or Cell Chemical Biology, depending on whether the central claim is mechanistic or translational. The question to answer before you choose is simple: is the paper's main contribution a chemical result, or a biological or clinical one? Medicinal chemistry papers that are really pharmacology papers belong in pharmacology journals, and editors notice when a manuscript has been sent to the wrong readership.
Open Access, Charges and Agreements
Open access terms are where a journal switch most often goes wrong. Before you choose a new target, check three things: whether your institution has a publishing agreement with the journal's publisher, whether the journal is fully open access or hybrid, and what your funder requires. ACS has reported that its institutional open access agreements cover more than 70 percent of US-based authors who publish with it, as of early 2026. If your institution is covered, an ACS journal may cost you little more than a rival would. If it is not, the calculation looks different, and a rival with an agreement at your institution may be the better financial choice.
Funder rules add a second layer. Authors funded by the NIH need a compliant public access route, and ACS has described a zero-embargo green option for NIH-funded corresponding authors submitting to hybrid journals. Our guide to NIH zero-embargo public accessexplains the mechanics. Check the funder's current policy directly, not a publisher page that describes its own compliance.
Do not assume that a fully open access journal is cheaper for your lab. Its list price may be higher than a hybrid title's charge after your institutional discount. Compare the amount your institution would actually pay for each candidate, not the figure printed on the journal's homepage.
Re-Check the AI and Reporting Rules Before You Resubmit
Moving journals resets the paperwork. The AI disclosure you wrote for the ACS submission may sit in the wrong place for the next one. ACS's author guidelines, as summarized in its own publishing blog, say that AI tools cannot be authors and ask that text or image generation be disclosed in the Acknowledgments, with a description of when and how the tool was used. Other publishers ask for a separate statement near the end of the manuscript, a dedicated field in the submission system, or a note in a figure legend. The substance is similar, but the location is not, and a disclosure in the wrong section is exactly the kind of thing a checklist catches. Our guide to disclosing AI use in medical manuscripts covers the wording in more detail.
Reporting guidelines are the other trap. A paper declined by an ACS journal may have been submitted without a completed checklist, or with one mapped to the old template. Before you resubmit, match every item the new journal requests, whether that is CONSORT, STROBE, PRISMA or a field-specific equivalent. Then check that your data availability statement uses the new journal's wording and that the cover letter names the right article type. Editors who see a mismatch in the first screen rarely read the rest of the file with the same goodwill.
Transfer, Resubmit or Start Fresh
Once you have a shortlist, decide how the paper will move. Some publishers offer a transfer, in which the rejecting editor forwards the manuscript and reviewer reports to a sister journal. Transfers can save weeks, but they are not automatic, and the receiving editor is not obliged to treat the earlier reviews as sufficient. Ask whether a transfer is available through the decision letter or the editorial office, and do not assume it. Our guide to journal manuscript transfer cascades explains how these arrangements usually work.
If you resubmit cold, use the reviewers' comments honestly. Revise the paper in response to them even when the new journal will not have the same reviewers, and describe the changes in the cover letter. Say what changed in the methods, the analyses and the framing. Avoid any suggestion that the previous journal simply got it wrong. Editors read cover letters for tone as much as for content, and a letter that relitigates the last decision sets a poor tone for the next one.
The common error is to send an unchanged manuscript to three journals in sequence. Each rejection often reveals a problem the authors have not solved, and an unchanged resubmission usually brings back the same reviewer comments at the next stop. Two or three rounds of that can cost a year.
A shortlist check for every candidate journal
- Does the scope name your question, and do recent articles match your method?
- Does the article type fit, and do the word, figure and reference limits work?
- What does your institution or funder actually pay, and is the journal fully open access or hybrid?
- Where does the AI disclosure go, and which reporting checklist is required?
- Is a transfer offered, and how long do decisions take in the journal's recent records?
Frequently Asked Questions
What are the best ACS Publications alternatives for chemistry papers?
There is no single answer. For broad, high-ambition chemistry, Angewandte Chemie, Chem and Nature Chemistry are the usual comparators, while Chemical Science and Communications Chemistry offer open access routes. The right choice depends on why the paper was declined and on the subfield it belongs to.
Are there journals like ACS for medicinal chemistry?
European Journal of Medicinal Chemistry, RSC Medicinal Chemistry and ChemMedChem are common options. Read recent articles in each and check whether your study design, compound class and claims resemble what they publish.
Can I send a rejected ACS paper straight to another journal?
Yes, provided you have not agreed to a transfer and you have revised the paper in response to the reviews. Read the new journal's rules on prior submissions, and answer any question about earlier rejections in the submission system accurately.
What to Do Next
Start with the decision letter and write down the reason for rejection in one sentence. Then build a shortlist of three journals that match that reason, not three journals that match your ambitions. Check each candidate against the list above, including its recent articles, its open access cost to your institution, its AI disclosure location and its reporting checklist. Decide whether a transfer is worth asking for, and if not, prepare a revised manuscript and a cover letter that explains what changed.
Most authors who move from an ACS journal succeed on the second or third try, not because the paper became better overnight, but because the next choice was deliberate. A journal picked for a reason, with its rules checked before submission, is a far stronger bet than one picked from the first search result. Treat the next decision as a research task in its own right, and give it the same care you gave the paper.
Further Reading
Best Chemistry Journals
A field-by-field overview for choosing a first target.
Journal Rejection: What to Do Next
A structured response to a decline letter before you pick a new journal.
Journal Manuscript Transfer Cascades
How transfer arrangements work and when to ask for one.
How to Choose the Right Journal
A fit-first method for picking a target before you submit.
Written by Dr. Meng Zhao
Physician-Scientist · Founder, LabCat AI
MD · Former Neurosurgeon · Medical AI Researcher
Dr. Meng Zhao is a former neurosurgeon turned medical-AI researcher. After years in the operating room, he moved into applied AI for clinical workflows and now leads LabCat AI, a medical-AI company working on decision support and research tooling for clinicians. He built Journal Metrics as a free resource for researchers who need reliable journal metrics without paid database subscriptions.
New on PubMed
What's new in your field?
Type a topic to see the newest PubMed papers from the past week and the big picture of what they found, summarized by Claude on the Pro plan. Get a free weekly email to keep up.
See a demo:GLP-1CRISPRLong COVID
Related Articles
Rejected from JACC? Similar Cardiology Journals to Submit to Next
Journals like JACC for cardiology papers that missed the cut: how to read the rejection, and realistic next targets across the ACC family, the AHA, the ESC, JAMA Cardiology and BMJ Heart.
9 min readPublishing GuideRejected from NEJM? 8 Similar Journals to Submit to Next
Journals like NEJM for papers that missed the cut: how to read the rejection, and eight realistic next targets across the NEJM family, JAMA Network, Lancet, BMJ, Annals and PLOS Medicine.
9 min readPublishing GuideGetting Credit for Peer Review: What the 2026 Recognition Crisis Means for Medical Academics
A 2026 commentary in the Journal of General Internal Medicine argues that peer review remains largely invisible in academic promotion. Here is what medical researchers who review can do now to document the work, earn CME credit, and make the contribution visible when it matters.
16 min read